Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
equine encephalitis vaccine
- Development stage
- Unknown
- Lead developer
- Bavarian Nordic
- Modality
- Vaccines & Immunotherapeutics
01
Overview
The Equine Encephalitis vaccine is a trivalent vaccine candidate designed to provide protection against Eastern Equine Encephalitis Virus (EEEV), Western Equine Encephalitis Virus (WEEV), and Venezuelan Equine Encephalitis Virus (VEEV). Developed using the VesiculoVax platform—a recombinant Vesicular Stomatitis Virus (rVSV) vector technology—the vaccine was originally created by Profectus BioSciences and subsequently licensed by Emergent BioSolutions. These alphaviruses are significant public health threats and are classified as high-priority biodefense targets due to their potential for aerosol transmission and the severity of the neurological disease they cause in humans. The vaccine utilizes an attenuated rVSV vector to express the envelope glycoproteins of the three target viruses, eliciting a robust immune response including neutralizing antibodies.
- Other names
- Trivalent Equine Encephalitis VaccineVEE/EEE/WEE VaccineEquine Encephalitis (VEE, EEE, WEE) Vaccine
02
Targets
EEEV envelope glycoprotein (Eastern equine encephalitis virus envelope glycoprotein)VEEV envelope glycoprotein (Venezuelan equine encephalitis virus envelope glycoprotein)Western equine encephalitis virus envelope glycoprotein
Beyond the preview
Go deeper on equine encephalitis vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on equine encephalitis vaccine.